Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Robert J Petrella,1 Guy Tremblay,2 Guy De Backer,3 Dawn P Gill,4,5,6 On behalf of the POWER survey Study Group 1Department of Family Medicine and Cardiology, Lawson Health Research Institute, University of Western Ontario, ON, Canada; 2Centre hospitalier universitaire de Québec, Hôpital du Saint-Sacrement, Sainte-Foy, Québec, QC, Canada; 3Department of Public Health, Ghent University, Ghent, Belgium; 4Aging, Rehabilitation and Geriatric Care Research Centre, Lawson Health Research Institute, London, ON, Canada; 5School of Health Studies, Western University, London, ON, Canada; 6Department of Epidemiology, University of Washington, Seattle, WA, USA Purpose/introduction: The Canadian Hypertension Education Program (CHEP) has identified blood pressure (BP) control as a key target for an overall reduction in cardiovascular disease risk. The POWER survey (Physicians’ Observational Work on Patient Education According to their Vascular Risk) used Framingham methodology to investigate the impact of an angiotensin-receptor-blocker-based regimen on arterial BP and total coronary heart disease (CHD) risk in a subset of patients recruited in Canada. Methods: 309 Canadian practices screened for patients with either newly diagnosed or uncontrolled mild/moderate hypertension (sitting systolic blood pressure [SBP] >140 mmHg with diastolic blood pressure [DBP]